Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in TG Therapeutics, Inc. or BioMarin Pharmaceutical Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc. compare based on key financial metrics to determine which better meets your investment needs.

About TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Latest Biotechnology and TG Therapeutics, Inc., BioMarin Pharmaceutical Inc. Stock News

As of November 28, 2025, TG Therapeutics, Inc. had a $4.9 billion market capitalization, compared to the Biotechnology median of $222.5 million. TG Therapeutics, Inc.’s stock is up 10.5% in 2025, up 9.2% in the previous five trading days and down 3.9% in the past year.

Currently, TG Therapeutics, Inc.’s price-earnings ratio is 12.0. TG Therapeutics, Inc.’s trailing 12-month revenue is $531.9 million with a 84.1% net profit margin. Year-over-year quarterly sales growth most recently was 92.7%. Analysts expect adjusted earnings to reach $2.875 per share for the current fiscal year. TG Therapeutics, Inc. does not currently pay a dividend.

As of November 28, 2025, BioMarin Pharmaceutical Inc. had a $10.7 billion market cap, putting it in the 80th percentile of all stocks. BioMarin Pharmaceutical Inc.’s stock is down 14.9% in 2025, up 6.6% in the previous five trading days and down 14.07% in the past year.

Currently, BioMarin Pharmaceutical Inc.’s price-earnings ratio is 20.9. BioMarin Pharmaceutical Inc.’s trailing 12-month revenue is $3.1 billion with a 16.8% net profit margin. Year-over-year quarterly sales growth most recently was 4.1%. Analysts expect adjusted earnings to reach $3.577 per share for the current fiscal year. BioMarin Pharmaceutical Inc. does not currently pay a dividend.

How We Compare TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc. Stock Value Grades

Company	Ticker	Value
TG Therapeutics, Inc.	TGTX	D
BioMarin Pharmaceutical Inc.	BMRN	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

TG Therapeutics, Inc. has a Value Score of 21, which is Expensive. BioMarin Pharmaceutical Inc. has a Value Score of 41, which is Average.

The Value Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc. or BioMarin Pharmaceutical Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc. or BioMarin Pharmaceutical Inc. is the better investment when it comes to value.

TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc. Growth Grades

Company	Ticker	Growth
TG Therapeutics, Inc.	TGTX	F
BioMarin Pharmaceutical Inc.	BMRN	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

TG Therapeutics, Inc. has a Growth Score of 12, which is Very Weak. BioMarin Pharmaceutical Inc. has a Growth Score of 87, which is Very Strong.

The Growth Grade Winner: BioMarin Pharmaceutical Inc.

As you can clearly see from the Growth Grade breakdown above, BioMarin Pharmaceutical Inc. has a more attractive growth grade than TG Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, BioMarin Pharmaceutical Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
TG Therapeutics, Inc.	TGTX	C
BioMarin Pharmaceutical Inc.	BMRN	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

TG Therapeutics, Inc. has a Earnings Estimate Score of 60, which is Neutral. BioMarin Pharmaceutical Inc. has a Earnings Estimate Score of 36, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc. or BioMarin Pharmaceutical Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc. or BioMarin Pharmaceutical Inc. is the better investment when it comes to estimate revisions.

Other TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc. Grades

In addition to Value, Growth and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, TG Therapeutics, Inc. or BioMarin Pharmaceutical Inc. Stock?

Overall, TG Therapeutics, Inc. stock has a Value Score of 21, Growth Score of 12 and Estimate Revisions Score of 60.

BioMarin Pharmaceutical Inc. stock has a Value Score of 41, Growth Score of 87 and Estimate Revisions Score of 36.

Comparing TG Therapeutics, Inc. and BioMarin Pharmaceutical Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.